Phlorizin attenuates chronic kidney disease induced bone loss by mitigating sclerostin mediated inhibition of Wnt/β-catenin signaling and ameliorating metabolic alterations.

Article D Peer reviewed Preclinical

Key takeaways

In mice with kidney disease, the drug combination improved renal function. This was seen in both male and female mice.

Rathur R · Ubaid M · Goswami A · Tomar MS · Srivastava S · Trivedi AK · Srivastava A · Srivastava KR · Singh D

Article · PubMed, the drug frontier · 2026 Aug 13
https://pubmed.ncbi.nlm.nih.gov/42594745/